1.1Lower first dextromethorphan strength
A tablet press compresses a blend of both active ingredients, microcrystalline cellulose, and a disintegrant. The first tablet supplies 25 mg less dextromethorphan than the 45 mg second dosage form.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A tablet press compresses a blend of both active ingredients, microcrystalline cellulose, and a disintegrant. The first tablet supplies 25 mg less dextromethorphan than the 45 mg second dosage form.
A tablet press meters the two active ingredients into separate layers of a single tablet. The bupropion layer delivers the same amount as the first dosage form, and the dextromethorphan layer delivers 30 mg more.
Water-soluble salts of both active ingredients dissolve in buffered water. Two concentrations of dextromethorphan supply the two strengths at a common fill volume, and sealed single-dose vials dispense the full volume.
A classified middle fraction supplies most of the particle volume, and smaller and larger fractions provide the lower and upper tails. Laser diffraction verifies the volume median after the fractions are blended.
An air classifier separates the finest particles from the feed. The retained fine fraction is blended with middle and coarse fractions so that 10 percent of the measured particle volume falls below a diameter of 40 to 50 μm.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An analytical training kit contains separate sealed sets of the 105 mg bupropion hydrochloride and 30 mg dextromethorphan units and the 105 mg bupropion hydrochloride and 45 mg dextromethorphan units. A third compartment holds sealed aliquots from the microparticle lot used to make one set of units. Trainees disperse the reference aliquots in a laser diffraction instrument and compare the measured 10th, 50th, and 90th percentiles with the values recorded for the lot.
A dynamic image analyzer replaces the laser diffraction instrument for characterization of the microparticle lot. A dry feeder spreads the particles across a backlit imaging zone, and a camera records their silhouettes. Software segments isolated silhouettes, calculates the diameter of a circle with the same projected area as each silhouette, and reports the 10th, 50th, and 90th percentiles of the resulting count distribution.
The two dosage forms retain 105 mg of bupropion hydrochloride per unit and use 30 mg and 45 mg of dextromethorphan, respectively. The microparticle lot has laser diffraction targets of 15 to 25 μm at the 10th percentile, 55 to 75 μm at the median, and 130 to 170 μm at the 90th percentile. A vibratory sieve separates size fractions, and measured amounts of those fractions are recombined and checked by laser diffraction before the lot enters dosage form production.
The two strengths occupy separate blister cards in one carton, with a two-dimensional barcode on each card and on the carton. The carton barcode identifies the kit, and each card barcode identifies the strength, lot, and expiration date. At stocking and dispensing, a scanner reads the codes and pharmacy inventory software verifies that the two card strengths match the kit record.
A blister packaging line fills and seals separate cards for the 30 mg and 45 mg dextromethorphan strengths, with 105 mg of bupropion hydrochloride in each dosage unit. A camera reads the printed strength and lot code on each sealed card as it enters the cartoning station. The cartoner places one card of each strength into a carton and diverts assemblies with unreadable codes or duplicate strengths.
An automated sampler withdraws aliquots from a moving microparticle stream at scheduled intervals before the particles enter the dosage form blender. A dry dispersion module feeds each aliquot into a laser diffraction instrument, and the controller records the 10th, 50th, and 90th percentiles with the sample time and lot identifier. The controller flags the lot for review when a measured percentile falls outside its configured range.
One tablet layer contains 105 mg of bupropion hydrochloride in a hydroxypropyl methylcellulose matrix. A second layer contains dextromethorphan hydrobromide in an amount that supplies 30 mg of dextromethorphan on a free-base basis, with croscarmellose sodium to promote disintegration.
A hard capsule contains bupropion hydrochloride microparticles blended with mannitol and dextromethorphan hydrobromide granules. The capsule shell dissolves after ingestion and releases the particulate fill.
A dry powder feeder disperses a representative sample in an air stream through a laser diffraction instrument. The instrument calculates the cumulative particle volume distribution and reports a median diameter of 75 μm.
A classified coarse fraction is blended with finer bupropion-containing microparticles. Laser diffraction verifies a 90th percentile diameter of 250 μm on a cumulative volume basis.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The oral dosage form of embodiment 16, wherein about 30 mg to about 350 mg of dextromethorphan is present in the dosage form. The oral dosage form of embodiment 16 or 17, wherein about 100 mg to about 400 mg of bupropion is present in the dosage form.B · US 10,874,663 B2 · ¶ 453
The oral dosage form of embodiment 16, wherein about 30 mg to about 350 mg of dextromethorphan is present in the dosage form. The oral dosage form of embodiment 16 or 17, wherein about 100 mg to about 400 mg of bupropion is present in the dosage form.B · US 10,874,663 B2 · ¶ 453
A panel of lotion formulations, thickened with microparticles of D,L-γ-poly(glutamate) cross-linked with the ethylene glycol diglycidyl ether (prepared similarly to Example 1) at dispersions of 0.25% w/v, 0.5% w/v, and 1% w/v, was prepared as per the following procedure: 1.A · US 2020/0095386 A1 · ¶ 60
The rheology modifier composition of this invention includes cross-linked poly(amino acid) particles with a mean equivalent spherical diameter (that is, diameter of a sphere of equivalent volume to the mean volume of the particles) when fully swollen in deionized water of up to about 1000 μm (measured by laser diffraction.A · US 2020/0095386 A1 · ¶ 29
An empty cell means only that no passage was reproduced there.
However, the thickening potency of these materials is generally limited and may be adversely affected by an aqueous matrix composition; particularly, thickening potency is often reduced in the presence of electrolytes, especially polyvalent metal cations such Ca2+ and Mg2+.A · US 2020/0095386 A1 · ¶ 6
There is thus a need to produce biobased, non-toxic, and biodegradable thickeners that can offer performance parity with conventional synthetic carboxyl-containing polymers based on ethylenically unsaturated monomers.A · US 2020/0095386 A1 · ¶ 8
Some embodiments include a method of increasing dextromethorphan plasma levels in a human being, comprising co-administering bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds with dextromethorphan.B · US 10,874,663 B2 · ¶ 2
Some embodiments include a method of reducing an adverse event associated with treatment by dextromethorphan, comprising co-administering threohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human patient in need of dextromethorphan treatment, wherein the human patient is at risk of experiencing the adverse event as a result of being treated with dextromethorphan.B · US 10,874,663 B2 · ¶ 7
patent.fyi, US 2026/0355130 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355130/, SHA-256 dc8f1136ad149a077be65b2ca8f34b2cbbc9ccd2b5c250516d22b1c48c775887